Literature DB >> 820194

Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis.

J R Gill, J C Frölich, R E Bowden, A A Taylor, H R Keiser, H W Seyberth, J A Oates, F C Bartter.   

Abstract

Urinary prostaglandins E2 and F2alpha were measured by gas chromatography-mass spectrometry in three adult women and an adolescent girl with Bartter's syndrome. On a constant metabolic diet prostaglandin E2 ranged from 293 to 1,221 ng/day (mean, 640 ng/day) and exceeded the normal range for adults of 76 to 281 ng/day in all patients. Prostaglandins F2alpha ranged from 291 to 1,061 ng/day (mean, 747 ng/day) in the adult women. Only in a young girl did prostaglandins F2alpha (1,677 ng/day) clearly exceed the normal range for adults of 422 to 871 ng/day. Treatment with indomethacin, which decreased urinary prostaglandin E-like material by 69 per cent or more, did not affect blood pressure. Plasma renin activity, which ranged from 5.2 to 22.2 ng/ml/hour (patients supine) and from 23.3 to 30.4 ng/ml/hour (patients upright), and urinary aldosterone, which ranged from 14.0 to 45.6 ng/day, decreased by 79, 65 and 52 per cent, respectively. The clearance of creatinine was lower for the eight or nine days of treatment, the balances of sodium and potassium were positive, and serum potassium was higher than in control. Ibuprofen, an inhibitor of prostaglandin synthetase which differs in structure from indomethacin, produced metabolic effects which were qualitatively similar to those of indomethacin. The results indicate that the renal synthesis of prostaglandins is increased in Bartter's syndrome and that prostaglandins mediate the hyperreninemia and hyperaldosteronism which characterize the disorder. The over-production of prostaglandins by the kidney could be proximal cause of the syndrome, or secondary to intrarenal changes of an unknown nature. This study provides additional evidence for an important role for prostaglandins in the release of renin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820194     DOI: 10.1016/0002-9343(76)90029-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  46 in total

Review 1.  The pathophysiological and molecular basis of Bartter's and Gitelman's syndromes.

Authors:  S Bhandari
Journal:  Postgrad Med J       Date:  1999-07       Impact factor: 2.401

Review 2.  Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome.

Authors:  H W Seyberth
Journal:  Klin Wochenschr       Date:  1978-04-15

3.  Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation.

Authors:  Thomas P Cappola; Scot J Matkovich; Wei Wang; Derek van Booven; Mingyao Li; Xuexia Wang; Liming Qu; Nancy K Sweitzer; James C Fang; Muredach P Reilly; Hakon Hakonarson; Jeanne M Nerbonne; Gerald W Dorn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-19       Impact factor: 11.205

4.  Bartter's syndrome, nephrocalcinosis and renal insufficiency.

Authors:  A Pierratos; R A Couture; P J Hierlihy; R C Bell; D Z Levine
Journal:  CMAJ       Date:  1989-11-15       Impact factor: 8.262

Review 5.  The genomic architecture of sporadic heart failure.

Authors:  Gerald W Dorn
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

6.  [Secondary gout and pseudo-Bartter syndrome in females with laxative abuse].

Authors:  O Adam; F D Goebel
Journal:  Klin Wochenschr       Date:  1987-09-01

7.  Treatment of Bartter's syndrome in early childhood with prostaglandin synthetase inhibitors.

Authors:  J M Littlewood; M R Lee; S R Meadow
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

8.  Changes of vasoactive substances following embolization for renal cell carcinoma.

Authors:  T Nakada; H Koike; T Katayama
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

9.  Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine.

Authors:  G Ciabattoni; F Pugliese; M Spaldi; G A Cinotti; C Patrono
Journal:  J Endocrinol Invest       Date:  1979 Apr-Jun       Impact factor: 4.256

10.  [Reduced urinary prostaglandin E2-excretion and diminished responsiveness of plasma renin activity in patients with essential hypertension (author's transl)].

Authors:  B Scherer; E Held; H H Lange; P C Weber
Journal:  Klin Wochenschr       Date:  1979-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.